With their first technology platform company, Procorde , the founders have initiated most of the current projects. During this period, cooperations with large enterprises (e.g. Aventis) have been carried out successfully.


Starting 2007, relevant funding of the successor company Corimmun allowed further clinical development of the most promising drugs. In addition, the founding team succeeded in the acquisition of award-winning “GoBio” projects of the Federal Ministry of Research and Technology (BMBF) and in the participation in “m4”, BMBF’s biotechnology cluster. In June 2012, Corimmun GmbH was sold to Janssen-CILAG GmbH, Neuss, a subsidiary of Johnson + Johnson, New Brunswick, NJ, USA.


During this transaction, all rights on COR-1 were transferred to Janssen-CILAG – the remaining projects have been pursued under the company name advanceCOR.

The further clinical development of COR-1 is currently being organized by the University of Würzburg, Germany, which still holds the proprietary rights on the patents. An additional phase IIb study is currently being prepared at the German Comprehensive Heart Failure Centre (EudraCT 2015-002010-68)

Cookie Preference

Please select an option. You can find more information about the consequences of your choice at Help. Datenschutz | Impressum

Select an option to continue

Your selection was saved!

More information


To continue, you must make a cookie selection. Below is an explanation of the different options and their meaning.

  • Accept all cookies:
    All cookies such as tracking and analytics cookies.
  • Accept first-party cookies only:
    Only cookies from this website.
  • Reject all cookies:
    No cookies except for those necessary for technical reasons are set. Borlabs Cookie already set a necessary cookie.

You can change your cookie setting here anytime: Datenschutz. Impressum